Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

Shares of Akero Therapeutics ($AKRO) skyrocketed on Monday following game-changing results from its lead drug, efruxifermin, ...

Albay is home to the first Endoscopy Unit with Endoscopic Ultrasound (EUS) in Bicol Region, Southern Luzon and Visayas. EUS ...

Discover why Exact Sciences, a leading oncology diagnostics company, may see growth in the cancer diagnostics market with its ...

UC Davis Health, a university hospital in Sacramento, California, has become the first customer to order the EndoDrill GI ...

A Cleveland Clinic study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) ...

Akero Therapeutics shares gained 106% before the bell on Monday after the company reported results from a mid-stage trial studying its lead drug in patients with a type of liver disease.

Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating ...

Results showing Akero’s efruxifermin improved fibrosis by more than what Wall Street expected lifted the stock of both it and rival MASH developer 89bio.

Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...

A Cleveland Clinic study reveals that bariatric surgery significantly reduces the risk of serious liver complications in ...